JWJingwen Wei

Jingwen Wei

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Jingwen Wei has a total of 8 co-authors. Here are the top co-authors by number of shared publications:

  • Banghua Liao

    Department of Urology and Institute of Urology, West China Hospital Sichuan University Chengdu Sichuan People's Republic of China

    2 shared publications
  • Deyi Luo

    Department of Urology, West China Hospital, Sichuan University, Chengdu, China

    2 shared publications
  • Jiawei Chen

    Department of Urology, West China Hospital, Sichuan University, Chengdu, China

    2 shared publications
  • Tianyue Li

    Department of Urology and Institute of Urology, West China Hospital Sichuan University Chengdu Sichuan People's Republic of China

    2 shared publications
  • Xingpeng Di

    Department of Urology and Institute of Urology West China Hospital Sichuan University Chengdu P.R. China

    2 shared publications
  • Ya Li

    Department of Urology and Institute of Urology (Laboratory of Reconstructive Urology) West China Hospital, Sichuan University Chengdu PR China

    2 shared publications

Latest Publications

  • Open Access

    Crosstalk Between Cancer‐Associated Fibroblasts and Immune Cells: Mechanisms and Therapeutic Implications

    by Ya Li, Xingpeng Di, Jiawei Chen, Jingwen Wei, Tianyue Li, Kunjie Wang, Banghua Liao, Deyi Luo

    Cancer‐associated fibroblasts (CAFs) in the tumor microenvironment (TME) interact with multiple immune cells, such as T cells, macrophages, neutrophils, and other immune cells, to display both antitumor or protumor effects. Despite enormous progress in immunotherapy, the CAF‐associated resistance of immunotherapy is still urgent to be solved. In this review, we summarize the origins and heterogeneity of CAFs in the TME, including the subpopulations of CAFs and their biological function. Then we discuss the communications between CAFs and tumor‐associated macrophages, T lymphocytes, tumor‐associated neutrophils, and other immune cells. CAFs cannot only recruit immune cells in the TME, but also trigger polarization, proliferation, infiltration of immune cells, thereby promoting tumor progression. Inversely, some immune cells promote the recruitment, transdifferentiation, and proliferation of CAFs. We also focus on the current progress in therapeutic strategies targeting CAF‐elimination, CAF‐reprograming, downstream signaling blockade, and CAF‐induced extracellular matrix barrier elimination to enhance the efficacy of immunotherapy and related clinical trials. Overall, we aim to provide the conceptions of CAF‐immunocyte crosstalk in the TME and application of immunotherapy, paving the way for the development of precise and individualized strategies through clarifying the interaction between CAFs and immunocytes.


  • Open Access

    Crosstalk between fibroblasts and immunocytes in fibrosis: From molecular mechanisms to clinical trials

    by Xingpeng Di, Jiawei Chen, Ya Li, Menghua Wang, Jingwen Wei, Tianyue Li, Banghua Liao, Deyi Luo

    Background: The impact of fibroblasts on the immune system provides insight into the function of fibroblasts. In various tissue microenvironments, multiple fibroblast subtypes interact with immunocytes by secreting growth factors, cytokines, and chemokines, leading to wound healing, fibrosis, and escape of cancer immune surveillance. However, the specific mechanisms involved in the fibroblast‐immunocyte interaction network have not yet been fully elucidated.Main body and conclusion: Therefore, we systematically reviewed the molecular mechanisms of fibroblast‐immunocyte interactions in fibrosis, from the history of cellular evolution and cell subtype divisions to the regulatory networks between fibroblasts and immunocytes. We also discuss how these communications function in different tissue and organ statuses, as well as potential therapies targeting the reciprocal fibroblast‐immunocyte interplay in fibrosis. A comprehensive understanding of these functional cells under pathophysiological conditions and the mechanisms by which they communicate may lead to the development of effective and specific therapies targeting fibrosis.